Pre-made Lokivetmab benchmark antibody ( Canine Whole mAb, anti-IL31 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-319-1mg	1mg	3090
GMP-Bios-ab-319-10mg	10mg	Inquiry
GMP-Bios-ab-319-100mg	100mg	Inquiry
GMP-Bios-ab-319-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody
INN Name	Lokivetmab
Target	IL31
Format	Canine Whole mAb
Derivation	Caninized
Species Reactivity	Canine
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	NFD
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	Zoetis
Conditions Approved	Canine atopic dermatitis
Conditions Active	na
Conditions Discontinued	na
Development Tech	na